20Mar 2024
Meta-Analysis Uncovers Best Adjuvant Therapies for Renal Cell Carcinoma

Meta-Analysis Uncovers Best Adjuvant Therapies for Renal Cell Carcinoma

A study assessed the efficacy of post-nephrectomy adjuvant therapies in renal cell carcinoma (RCC) patients and determined optimal intervention choices. Seven studies with 7548 participants were analyzed. Immune checkpoint inhibitors (ICIs) showed disease-free survival (DFS) benefit in female patients and those with high PD-L1 expression, sarcomatoid features, and M0 intermediate-high risk. Network meta-analyses revealed pembrolizumab's superiority in DFS and overall survival (OS) compared to other therapies. Patients with sarcomatoid differentiation and high PD-L1 expression were more responsive to ICIs. These findings emphasize the potential of tailored adjuvant therapy selection in post-nephrectomy RCC patients.

  • #nephrology

Like

Save

Share